We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+71.33%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$910M
AUM Growth
+$326M
Cap. Flow
+$35.9M
Cap. Flow %
3.94%
Top 10 Hldgs %
64.43%
Holding
33
New
2
Increased
10
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$22.8M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$19.9M
3
BPMC
Blueprint Medicines
BPMC
+$15.4M
4
SAGE
Sage Therapeutics
SAGE
+$12.7M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.53M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$50.4M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$6.41M
3
IBB icon
iShares Biotechnology ETF
IBB
+$5.79M
4
NVTA
Invitae Corporation
NVTA
+$3.53M
5
GNMK
GenMark Diagnostics, Inc
GNMK
+$2.96M

Sector Composition

Rank Sector Weight
1 Healthcare 79.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONCE
1
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$107M 11.76%
940,000
+100,000
+12% +$7.35M
BPMC
2
DELISTED
Blueprint Medicines
BPMC
$67.9M 7.46%
848,648
+208,648
+33% +$15.4M
MYOK
3
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$66.8M 7.34%
1,285,000
+495,000
+63% +$22.8M
SAGE
4
DELISTED
Sage Therapeutics
SAGE
$63.6M 6.99%
400,000
+88,000
+28% +$12.7M
BLUE
5
DELISTED
bluebird bio
BLUE
$56.2M 6.18%
27,599
+2,123
+8% +$3.74M
NVTA
6
DELISTED
Invitae Corporation
NVTA
$51.5M 5.66%
2,200,000
-200,000
-8% -$3.53M
FATE icon
7
Fate Therapeutics
FATE
$294M
$44.8M 4.92%
2,550,000
– –
DNTH icon
8
Dianthus Therapeutics
DNTH
$5.72B
$43.5M 4.78%
165,207
– –
BLFS icon
9
BioLife Solutions
BLFS
$1.56B
$43.4M 4.77%
2,428,571
– –
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$29.1B
$41.6M 4.57%
445,000
+90,000
+25% +$7.53M
CDXS icon
11
Codexis
CDXS
$157M
$41.6M 4.57%
2,025,000
– –
BOLD
12
DELISTED
Audentes Therapeutics, Inc
BOLD
$39.4M 4.33%
1,010,000
+150,000
+17% +$4.3M
SRPT icon
13
Sarepta Therapeutics
SRPT
$1.63B
$36.4M 3.99%
305,000
+155,000
+103% +$19.9M
GNMK
14
DELISTED
GenMark Diagnostics, Inc
GNMK
$23.9M 2.62%
3,365,000
-450,000
-12% -$2.96M
AGIO icon
15
Agios Pharmaceuticals
AGIO
$1.84B
$22.6M 2.48%
335,000
-110,000
-25% -$6.41M
VYGR icon
16
Voyager Therapeutics
VYGR
$179M
$21.6M 2.37%
1,128,075
– –
CNST
17
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$21.1M 2.32%
1,556,999
+1
+0% +$9
ILMN icon
18
Illumina
ILMN
$30.2B
$18.6M 2.05%
61,680
– –
GBT
19
DELISTED
Global Blood Therapeutics, Inc.
GBT
$15.9M 1.74%
300,000
-50,000
-14% -$2.46M
GRTS
20
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$14.9M 1.64%
1,120,586
+400,000
+56% +$5.35M
EDIT icon
21
Editas Medicine
EDIT
$399M
$11.7M 1.29%
480,000
– –
SGMO
22
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$10.3M 1.13%
1,080,000
– –
QTTB icon
23
Q32 Bio
QTTB
$460M
$9.71M 1.07%
19,444
– –
ONC
24
BeOne Medicines Ltd
ONC
$32.3B
$9.24M 1.02%
70,000
– –
EVH icon
25
Evolent Health
EVH
$359M
$6.92M 0.76%
550,000
– –
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Casdin Capital held 33 positions worth $910M, up 56% from $585M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Casdin Capital deployed $35.9M of net new capital in Q1 2019, opening 2 new positions and adding to 10 existing holdings. Its largest new stake was Alector: 331,039 shares worth $6.2M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was Agios Pharmaceuticals, an estimated $6.41M trimmed.

  • Casdin Capital's largest Q1 2019 buy was Alector: 331,039 shares worth $6.2M.
  • Casdin Capital added most to MyoKardia, Inc. Common Stock in Q1 2019, an estimated $22.8M increase.
  • Casdin Capital's biggest Q1 2019 reduction was Agios Pharmaceuticals, cutting an estimated $6.41M.
  • Casdin Capital fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $50.4M.
  • Casdin Capital's ten largest holdings make up 64% of its $910M portfolio in Q1 2019.
  • Casdin Capital opened 2 new positions and closed 4 in Q1 2019.
  • Casdin Capital's portfolio value rose 56% quarter-over-quarter to $910M.

Based on Casdin Capital's 13F filing for Q1 2019, filed 15 May 2019.